Your browser doesn't support javascript.
loading
Asymmetric Synthesis of α-Aminoboronates via Rhodium-Catalyzed Enantioselective C(sp3)-H Borylation.
Reyes, Ronald L; Sato, Miyu; Iwai, Tomohiro; Sawamura, Masaya.
Afiliação
  • Reyes RL; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD) , Hokkaido University , Sapporo 001-0021 , Japan.
  • Sato M; Department of Chemistry, Faculty of Science , Hokkaido University , Sapporo 060-0810 , Japan.
  • Iwai T; Department of Chemistry, Faculty of Science , Hokkaido University , Sapporo 060-0810 , Japan.
  • Sawamura M; Department of Chemistry, Faculty of Science , Hokkaido University , Sapporo 060-0810 , Japan.
J Am Chem Soc ; 142(1): 589-597, 2020 01 08.
Article em En | MEDLINE | ID: mdl-31820960
ABSTRACT
α-Aminoboronic acids, isostructural boron analogues of α-amino acids, have received much attention because of the important biomedical applications implicated for compounds containing this structure. Additionally, the inherent versatility of α-aminoboronic acids as synthetic intermediates through diverse carbon-boron bond transformations makes the efficient synthesis of these compounds highly desirable. Here, we present a Rh-monophosphite chiral catalytic system that enables a highly efficient enantioselective borylation of N-adjacent C(sp3)-H bonds for a range of substrate classes including 2-(N-alkylamino)heteroaryls and N-alkanoyl- or aroyl-based secondary or tertiary amides, some of which are pharmaceutical agents or related compounds. Various stereospecific transformations of the enantioenriched α-aminoboronates, including Suzuki-Miyaura coupling with aryl halides and the Rh-catalyzed reaction with an isocyanate derivative of α-amino acid, affording a new peptide chain elongation method, have been demonstrated. As a highlight of this work, the borylation protocol was successfully applied to the catalyst-controlled site-selective and stereoselective C(sp3)-H borylation of an unprotected dipeptidic compound, allowing remarkably streamlined synthesis of the anti-cancer drug molecule bortezomib and offering a straightforward route for the synthesis of privileged molecular architectures.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article